title: [Pleading to maintain hydroxychloroquine throughout Lupus pregnancies].
abstract: OBJECTIVE
  The use of Hydroxychloroquine (HCQ) during pregnancy has remained controversial for a long time. However, it is generally agreed that pregnancy per se increases disease activity in patients with systemic lupus erythematosus (SLE) and that withdrawal of HCQ at the onset of pregnancy may result in exacerbation of SLE. Therefore, stopping HCQ at the onset of pregnancy may result in exacerbation of SLE which could be detrimental to both mother and fetus.
  
  
  BACKGROUND
  The available data suggest that HCQ can be continued safely throughout pregnancy. After the first report by Parke of successful continuation of HCQ throughout gestation, more than 250 pregnancies resulting in live births have been reported and no increase in the rate of birth defects have been demonstrated. When studied, no retinal toxicity and ototoxicity have been found in the children. Data concerning lactation and HCQ treatment are rare. However, the amount of HCQ received by children through lactation seems very low.
  
  
  CONCLUSIONS
  For patients with SLE already taking HCQ, the benefits of continuing treatment with this medication throughout pregnancy seem to outweigh the hypothetical risks associated with its use. HCQ should probably be maintained throughout pregnancy in these patients with SLE and it does not seem necessary to advise against breastfeeding. Further studies with prospective follow-up of children exposed in utero to HCQ remain however needed to provide a definitive answer.
authors.affiliation: Service de médecine interne, CHU Pitié-Salpêtrière, 47-83, boulevard de l'Hôpital, 75651 Paris cedex 13, France. nathalie.costedoat@psl.ap-hop-paris.fr
authors.forename: N
authors.initials: N
authors.lastname: Costedoat-Chalumeau
authors.forename: Z
authors.initials: Z
authors.lastname: Amoura
authors.forename: D
authors.initials: D
authors.lastname: Le Thi Huong
authors.forename: B
authors.initials: B
authors.lastname: Wechsler
authors.forename: J-C
authors.initials: JC
authors.lastname: Piette
mesh_terms: D018501:Antirheumatic Agents / Q000009:adverse effects*; D018450:Disease Progression; D005260:Female; D006801:Humans; D006886:Hydroxychloroquine / Q000009:adverse effects*; D007774:Lactation / Q000187:drug effects; D008180:Lupus Erythematosus, Systemic / Q000188:drug therapy*; D011247:Pregnancy; D011248:Pregnancy Complications / Q000188:drug therapy*; D018570:Risk Assessment
chemical_list: D018501:Antirheumatic Agents; D006886:Hydroxychloroquine